Evolocumab

ApprovedUNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Carotid Artery Stenosis

Conditions

Carotid Artery Stenosis, Asymptomatic Carotid Artery Stenosis

Trial Timeline

Aug 28, 2020 → May 1, 2022

NCT ID

NCT04539223

About Evolocumab

Evolocumab is a approved stage product being developed by Amgen for Carotid Artery Stenosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT04539223. Target conditions include Carotid Artery Stenosis, Asymptomatic Carotid Artery Stenosis.

What happened to similar drugs?

2 of 5 similar drugs in Carotid Artery Stenosis were approved

Approved (2) Terminated (1) Active (2)

✅Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mgAstraZenecaApproved

✅Niacin/simvastatin compared to simvastatin alone at 2 dosesMerckApproved

🔄RosuvastatinAstraZenecaPhase 3

❌Rimonabant + Placebo (for Rimonabant)SanofiPhase 3

🔄Gadobutrol (Gadovist, BAY86-4875)BayerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (17)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06140095	Phase 1	UNKNOWN	Feb 1, 2024	Dec 1, 2025	Acute Metabolic Effects of Evolocumab and Atorvastatin
NCT04539223	Approved	UNKNOWN	Aug 28, 2020	May 1, 2022	Carotid Artery Stenosis
NCT03944577	Phase 2	Completed	Jul 15, 2019	Mar 28, 2023	Heart Transplant
NCT03331666	Approved	Terminated	Nov 16, 2018	Feb 4, 2020	Familial Hypercholesterolemia
NCT03403374	Approved	Completed	Aug 4, 2018	Nov 27, 2019	Homozygous Familial Hypercholesterolemia HoFH
NCT03096288	Approved	Completed	Oct 3, 2017	Nov 2, 2020	Atherosclerotic Cardiovascular Disease
NCT03080935	Phase 3	Terminated	Mar 13, 2017	Mar 4, 2022	Dyslipidemia
NCT02957604	Pre-clinical	Terminated	Dec 22, 2016	Sep 2, 2020	Hypercholesterolemia; ASCVD; Pregnancy
NCT02624869	Phase 3	Completed	Sep 10, 2016	Jun 1, 2021	Familial Hypercholesterolemia
NCT02867813	Phase 3	Completed	Sep 2, 2016	Mar 21, 2022	Dyslipidemia
NCT02585895	Phase 3	Completed	Dec 21, 2015	Jan 20, 2017	Hypercholesterolemia
NCT02304484	Phase 3	Completed	Nov 24, 2014	Mar 9, 2018	Hypercholesterolemia
NCT02275156	Phase 1	Completed	Aug 19, 2014	Dec 19, 2014	Hyperlipidemia
NCT01652703	Phase 2	Completed	Jul 10, 2012	—	Hypercholesterolemia and High Risk for Cardiovascular Events
NCT01624142	Phase 2/3	Completed	Jun 1, 2012	May 11, 2018	Severe Familial Hypercholesterolemia
NCT01439880	Phase 2	Completed	Oct 7, 2011	Jun 20, 2018	Hypercholesterolemia
NCT01380730	Phase 2	Completed	Jul 1, 2011	Apr 5, 2012	Hyperlipidemia

Competing Products

9 competing products in Carotid Artery Stenosis

See all competitors

Product	Company	Stage	Hype Score
Abciximab	Eli Lilly	Phase 1/2	24
Rosuvastatin	AstraZeneca	Phase 3	40
Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mg	AstraZeneca	Approved	39
Niacin/simvastatin compared to simvastatin alone at 2 doses	Merck	Approved	43
simvastatin + placebo	Merck	Pre-clinical	26
Atorvastatin/niacin extended-release + Atorvastatin + Simvastatin + Simvastatin	Merck	Phase 2	35
Atorvastatin - Cholestyramine - Sitosterol	Pfizer	Pre-clinical	26
Rimonabant + Placebo (for Rimonabant)	Sanofi	Phase 3	32
Gadobutrol (Gadovist, BAY86-4875)	Bayer	Phase 3	37